O	0	10	Adenovirus	Adenovirus	NN	B-NP
O	10	11	-	-	HYPH	B-NP
O	11	19	mediated	mediate	VBN	I-NP
O	20	24	gene	gene	NN	I-NP
O	25	33	transfer	transfer	NN	I-NP
O	34	36	of	of	IN	B-PP
O	37	47	endostatin	endostatin	NN	B-NP
O	48	50	in	in	FW	B-ADVP
O	51	55	vivo	vivo	FW	I-ADVP
O	56	63	results	result	VBZ	B-VP
O	64	66	in	in	IN	B-PP
O	67	71	high	high	JJ	B-NP
O	72	77	level	level	NN	I-NP
O	78	80	of	of	IN	B-PP
O	81	90	transgene	transgene	NN	B-NP
O	91	101	expression	expression	NN	B-NP
O	102	105	and	and	CC	O
O	106	116	inhibition	inhibition	NN	B-NP
O	117	119	of	of	IN	B-PP
B-Cancer	120	125	tumor	tumor	NN	B-NP
O	126	132	growth	growth	NN	I-NP
O	133	136	and	and	CC	O
O	137	147	metastases	metastasis	NNS	B-NP
O	147	148	.	.	.	O

O	149	159	Inhibition	Inhibition	NN	B-NP
O	160	162	of	of	IN	B-PP
O	163	175	angiogenesis	angiogenesis	NN	B-NP
O	176	179	has	have	VBZ	B-VP
O	180	184	been	be	VBN	I-VP
O	185	190	shown	show	VBN	I-VP
O	191	193	to	to	TO	I-VP
O	194	196	be	be	VB	I-VP
O	197	199	an	an	DT	B-NP
O	200	209	effective	effective	JJ	I-NP
O	210	218	strategy	strategy	NN	I-NP
O	219	221	in	in	IN	B-PP
B-Cancer	222	228	cancer	cancer	NN	B-NP
O	229	236	therapy	therapy	NN	I-NP
O	237	239	in	in	IN	B-PP
O	240	244	mice	mouse	NNS	B-NP
O	244	245	.	.	.	O

O	246	253	However	However	RB	B-ADVP
O	253	254	,	,	,	O
O	255	258	its	its	PRP$	B-NP
O	259	269	widespread	widespread	JJ	I-NP
O	270	281	application	application	NN	I-NP
O	282	285	has	have	VBZ	B-VP
O	286	290	been	be	VBN	I-VP
O	291	299	hampered	hamper	VBN	I-VP
O	300	302	by	by	IN	B-PP
O	303	315	difficulties	difficulty	NNS	B-NP
O	316	318	in	in	IN	B-PP
O	319	322	the	the	DT	B-NP
O	323	328	large	large	JJ	I-NP
O	328	329	-	-	HYPH	I-NP
O	329	334	scale	scale	NN	I-NP
O	335	345	production	production	NN	I-NP
O	346	348	of	of	IN	B-PP
O	349	352	the	the	DT	B-NP
O	353	367	antiangiogenic	antiangiogenic	JJ	I-NP
O	368	376	proteins	protein	NNS	I-NP
O	376	377	.	.	.	O

O	378	382	This	This	DT	B-NP
O	383	393	limitation	limitation	NN	I-NP
O	394	397	may	may	MD	B-VP
O	398	400	be	be	VB	I-VP
O	401	409	resolved	resolve	VBN	I-VP
O	410	412	by	by	IN	B-PP
O	413	415	in	in	FW	B-NP
O	416	420	vivo	vivo	FW	I-NP
O	421	429	delivery	delivery	NN	I-NP
O	430	433	and	and	CC	I-NP
O	434	444	expression	expression	NN	I-NP
O	445	447	of	of	IN	B-PP
O	448	451	the	the	DT	B-NP
O	452	466	antiangiogenic	antiangiogenic	JJ	I-NP
O	467	472	genes	gene	NNS	I-NP
O	472	473	.	.	.	O

O	474	476	We	We	PRP	B-NP
O	477	481	have	have	VBP	B-VP
O	482	493	constructed	construct	VBN	I-VP
O	494	495	a	a	DT	B-NP
O	496	507	recombinant	recombinant	JJ	I-NP
O	508	518	adenovirus	adenovirus	NN	I-NP
O	519	523	that	that	WDT	B-NP
O	524	533	expresses	express	VBZ	B-VP
O	534	540	murine	murine	JJ	B-NP
O	541	551	endostatin	endostatin	NN	I-NP
O	552	556	that	that	WDT	B-NP
O	557	559	is	be	VBZ	B-VP
O	560	572	biologically	biologically	RB	B-ADJP
O	573	579	active	active	JJ	I-ADJP
O	580	584	both	both	CC	O
O	585	587	in	in	FW	B-ADVP
O	588	593	vitro	vitro	FW	I-ADVP
O	593	594	,	,	,	O
O	595	597	as	as	IN	B-SBAR
O	598	608	determined	determine	VBN	B-VP
O	609	611	in	in	IN	B-PP
B-Cell	612	623	endothelial	endothelial	JJ	B-NP
I-Cell	624	628	cell	cell	NN	I-NP
O	629	642	proliferation	proliferation	NN	I-NP
O	643	649	assays	assay	NNS	I-NP
O	649	650	,	,	,	O
O	651	654	and	and	CC	O
O	655	657	in	in	FW	B-ADVP
O	658	662	vivo	vivo	FW	I-ADVP
O	662	663	,	,	,	O
O	664	666	by	by	IN	B-PP
O	667	678	suppression	suppression	NN	B-NP
O	679	681	of	of	IN	B-PP
O	682	694	angiogenesis	angiogenesis	NN	B-NP
O	695	702	induced	induce	VBN	B-VP
O	703	705	by	by	IN	B-PP
O	706	714	vascular	vascular	JJ	B-NP
O	715	726	endothelial	endothelial	JJ	I-NP
O	727	733	growth	growth	NN	I-NP
O	734	740	factor	factor	NN	I-NP
O	741	744	165	165	CD	I-NP
O	744	745	.	.	.	O

O	746	756	Persistent	Persistent	JJ	B-NP
O	757	761	high	high	JJ	I-NP
B-Organism_substance	762	767	serum	serum	NN	I-NP
O	768	774	levels	level	NNS	I-NP
O	775	777	of	of	IN	B-PP
O	778	788	endostatin	endostatin	NN	B-NP
O	789	790	(	(	(	O
O	790	793	605	605	CD	B-NP
O	793	794	-	-	HYPH	I-NP
O	794	798	1740	1740	CD	I-NP
O	799	801	ng	ng	NN	I-NP
O	801	802	/	/	SYM	B-NP
O	802	804	ml	ml	NN	I-NP
O	804	805	;	;	:	O
O	806	810	mean	mean	NN	B-NP
O	810	811	,	,	,	O
O	812	815	936	936	CD	B-NP
O	816	818	ng	ng	NN	I-NP
O	818	819	/	/	SYM	B-NP
O	819	821	ml	ml	NN	I-NP
O	821	822	)	)	)	O
O	823	827	were	be	VBD	B-VP
O	828	836	achieved	achieve	VBN	I-VP
O	837	842	after	after	IN	B-PP
O	843	851	systemic	systemic	JJ	B-NP
O	852	866	administration	administration	NN	I-NP
O	867	869	of	of	IN	B-PP
O	870	873	the	the	DT	B-NP
O	874	880	vector	vector	NN	I-NP
O	881	883	to	to	TO	B-PP
O	884	888	nude	nude	JJ	B-NP
O	889	893	mice	mouse	NNS	I-NP
O	893	894	,	,	,	O
O	895	900	which	which	WDT	B-NP
O	901	909	resulted	result	VBD	B-VP
O	910	912	in	in	IN	B-PP
O	913	924	significant	significant	JJ	B-NP
O	925	934	reduction	reduction	NN	I-NP
O	935	937	of	of	IN	B-PP
O	938	941	the	the	DT	B-NP
O	942	948	growth	growth	NN	I-NP
O	949	954	rates	rate	NNS	I-NP
O	955	958	and	and	CC	O
O	959	962	the	the	DT	B-NP
O	963	970	volumes	volume	NNS	I-NP
O	971	973	of	of	IN	B-PP
B-Cancer	974	976	JC	JC	NN	B-NP
I-Cancer	977	983	breast	breast	NN	I-NP
I-Cancer	984	993	carcinoma	carcinoma	NN	I-NP
O	994	997	and	and	CC	O
B-Cancer	998	1003	Lewis	Lewis	NNP	B-NP
I-Cancer	1004	1008	lung	lung	NN	I-NP
I-Cancer	1009	1018	carcinoma	carcinoma	NN	I-NP
O	1019	1020	(	(	(	O
O	1020	1021	P	P	NN	B-NP
O	1023	1027	less	less	JJR	B-NP
O	1028	1032	than	than	IN	I-NP
O	1034	1035	0	0	CD	I-NP
O	1035	1036	.	.	.	I-NP
O	1036	1039	001	001	CD	I-NP
O	1040	1043	and	and	CC	O
O	1044	1045	P	P	NN	B-NP
O	1047	1051	less	less	JJR	B-NP
O	1052	1056	than	than	IN	I-NP
O	1058	1059	0	0	CD	I-NP
O	1059	1060	.	.	.	I-NP
O	1060	1062	05	05	CD	I-NP
O	1062	1063	,	,	,	O
O	1064	1076	respectively	respectively	RB	B-ADVP
O	1076	1077	)	)	)	O
O	1077	1078	.	.	.	O

O	1079	1081	In	In	IN	B-PP
O	1082	1090	addition	addition	NN	B-NP
O	1090	1091	,	,	,	O
O	1092	1095	the	the	DT	B-NP
O	1096	1106	endostatin	endostatin	NN	I-NP
O	1107	1113	vector	vector	NN	I-NP
O	1114	1123	treatment	treatment	NN	I-NP
O	1124	1134	completely	completely	RB	B-ADVP
O	1135	1144	prevented	prevent	VBD	B-VP
O	1145	1148	the	the	DT	B-NP
O	1149	1158	formation	formation	NN	I-NP
O	1159	1161	of	of	IN	B-PP
B-Cancer	1162	1171	pulmonary	pulmonary	JJ	B-NP
I-Cancer	1172	1187	micrometastases	micrometastas	NNS	I-NP
O	1188	1190	in	in	IN	B-PP
B-Cancer	1191	1196	Lewis	Lewis	NNP	B-NP
I-Cancer	1197	1201	lung	lung	NN	I-NP
I-Cancer	1202	1211	carcinoma	carcinoma	NN	I-NP
O	1212	1213	(	(	(	O
O	1213	1214	P	P	NN	B-NP
O	1215	1216	=	=	SYM	B-VP
O	1217	1218	0	0	CD	B-NP
O	1218	1219	.	.	SYM	I-NP
O	1219	1223	0001	0001	CD	I-NP
O	1223	1224	)	)	)	O
O	1224	1225	.	.	.	O

O	1226	1245	Immunohistochemical	Immunohistochemical	JJ	B-NP
O	1246	1254	staining	staining	NN	I-NP
O	1255	1257	of	of	IN	B-PP
O	1258	1261	the	the	DT	B-NP
B-Cancer	1262	1268	tumors	tumor	NNS	I-NP
O	1269	1281	demonstrated	demonstrate	VBD	B-VP
O	1282	1283	a	a	DT	B-NP
O	1284	1293	decreased	decrease	VBN	I-NP
O	1294	1300	number	number	NN	I-NP
O	1301	1303	of	of	IN	B-PP
B-Multi-tissue_structure	1304	1309	blood	blood	NN	B-NP
I-Multi-tissue_structure	1310	1317	vessels	vessel	NNS	I-NP
O	1318	1320	in	in	IN	B-PP
O	1321	1324	the	the	DT	B-NP
O	1325	1334	treatment	treatment	NN	I-NP
O	1335	1340	group	group	NN	I-NP
O	1341	1347	versus	versus	IN	B-PP
O	1348	1351	the	the	DT	B-NP
O	1352	1360	controls	control	NNS	I-NP
O	1360	1361	.	.	.	O

O	1362	1364	In	In	IN	B-PP
O	1365	1375	conclusion	conclusion	NN	B-NP
O	1375	1376	,	,	,	O
O	1377	1380	the	the	DT	B-NP
O	1381	1388	present	present	JJ	I-NP
O	1389	1394	study	study	NN	I-NP
O	1395	1402	clearly	clearly	RB	B-ADVP
O	1403	1415	demonstrates	demonstrate	VBZ	B-VP
O	1416	1419	the	the	DT	B-NP
O	1420	1429	potential	potential	NN	I-NP
O	1430	1432	of	of	IN	B-PP
O	1433	1439	vector	vector	NN	B-NP
O	1439	1440	-	-	HYPH	O
O	1440	1448	mediated	mediate	VBN	B-NP
O	1449	1463	antiangiogenic	antiangiogenic	JJ	I-NP
O	1464	1468	gene	gene	NN	I-NP
O	1469	1476	therapy	therapy	NN	I-NP
O	1477	1479	as	as	IN	B-PP
O	1480	1481	a	a	DT	B-NP
O	1482	1491	component	component	NN	I-NP
O	1492	1494	in	in	IN	B-PP
B-Cancer	1495	1501	cancer	cancer	NN	B-NP
O	1502	1509	therapy	therapy	NN	I-NP
O	1509	1510	.	.	.	O

